Figures computed from official regulatory filings — .
Analysttarget 13 USD (+181%) · consensus 4.77/5 · 13 buy · 0 hold · 0 sell
Ownershipinsiders 9.45% · institutions 94.05% · short 16.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Taysha Gene Therapies, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
23 buys43 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Nagendran Sukumar | Sell | $1.2M | Unusual size | SEC |
| Stalfort John A IIItrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| DONENBERG PHILIP Btrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sepp-Lorenzino Laura | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Long Alison S | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Long Alison S | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stalfort John A IIItrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| DONENBERG PHILIP Btrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sepp-Lorenzino Laura | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nagendran Sukumar | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nagendran Sukumar | Exercise | $32.5K | SEC |
| Nagendran Sukumar | Sell | $892K | SEC |
| Alam Kamran | Sell | $7.5K | SEC |
| Nagendran Sukumar | Sell | $124.1K | SEC |
| Nagendran Sukumar | Sell | $423.4K | SEC |
| Nolan Sean P.track record | Sell | $190.4K | SEC |
| Alam Kamran | Sell | $109.9K | SEC |
| Nolan Sean P.track record | Sell | $649.7K | SEC |
| Alam Kamran | Sell | $375.1K | SEC |
| Nagendran Sukumar | Sell | $942K | Unusual size | SEC |
| Nolan Sean P.track record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nagendran Sukumar | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nagendran Sukumar | Exercise | $151.6K | SEC |
| Nagendran Sukumar | Exercise | $77.9K | SEC |
| Alam Kamran | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |